78 results found.
        
BARE BONES® - September 25, 2014
In connection with its previously-announced financial restatement plans, Orthofix determined that further data is required regarding inventory reserve amounts for Spine Fixation devices held as consign...
BARE BONES® - August 20, 2014
Orthofix will restate financial statements for FY11, '12 and 13 and 1Q14 by end of 3Q14. The company determined that certain entries in these statements were not properly accounted for...
BARE BONES® - May 7, 2014
Orthofix announced 1Q14 revenue of US $101.3MM, -2% from 1Q13. (BioStim $38.4MM, +1%; Biologics $13.0MM, -3%; Extremity Fixation $27.1MM, +4%; Spine Fixation $22.8MM, -11%) (
1Q14 Revenue: Orthofix
$101.3MM, -2% BioStim $38.4MM, +0.5% Biologics $13.0MM, -3% Extremity Fixation $27.1MM, +4% Spine Fixation $22.8MM, -11%   Growth drivers: stable Spine Stim, improving performance in Physio...
BARE BONES® - March 27, 2014
Orthofix announced 4Q13 revenue of US $106.1MM, -10% from 4Q12, and 2013 revenue of $400.5MM, -11% from 2012. (2013 by segment: BioStim $147.9MM, -20%; Biologics $53.8MM, flat...
4Q13/2013 Revenue: Orthofix
4Q13 revenue: of US $106.1MM, -10%   2013 revenue: of $400.5MM, -11% BioStim $147.9MM, -20% Biologics $53.8MM, flat (Trinity volume +5%) Extremity Fixation $103.4MM, -7% Spine Fixation $95...
BARE BONES® - March 25, 2014
Orthofix (OFIX) completed the filing of its previously-announced financial statement restatement, and will release 2013 earnings on 3/27/14. Independent Review, primarily focused on re...
BARE BONES® - February 13, 2014
Orthofix (OFIX) received an expected letter from NASDAQ stating that unless the company requests a Hearings Panel by 2/18/14, its stock will be subject to delisting. OFIX will...
BARE BONES® - February 6, 2014
Orthofix intends to complete restatement and filing of its Delinquent Reports (including the filing of its annual report for the year 2013) by the end of 1Q14. (
Web Exclusive: Highlights from THE SPINE MARKET report
In 2012, revenues generated by global sales of spinal implants and instrumentation reached an estimated $7.35 billion. Though historic double-digit growth in the segment flattened in 2010, looking ahead, conservative increases should occur based upon a shift in focus to more cervical discs, la...
BARE BONES® - August 7, 2013
An Audit Committee has concluded that certain of Orthofix’s previously issued consolidated financial statements should no longer be relied upon, after finding that certain revenues recognized during
BARE BONES® - May 8, 2013
Orthofix posted 1Q13 revenue of US $100.3MM, -13% from 1Q12. (Spine $66.3MM, -12%: Regenerative Stimulation $32.0MM, -18%, Repair/Biologics $34.3MM, -4%; Orthopaedics $33.9MM, -16%
1Q13 Revenue: Orthofix
$100.3MM, -13% Spine $66.3MM, -12% (Regenerative Stimulation $32.0MM, -18%; Implants/Biologics $34.3MM, -4%: Implants $23.7MM, -6%, Trinity Evolution +7%) Orthopaedics $33.9MM, -16%   ~1/3 of decrease in Spine due to sa...
BARE BONES® - February 21, 2013
Orthofix announced 2012 revenue of US $462.3MM, +0.4% from 2011, and 4Q12 revenue of $112MM, -8%. (4Q12 Spine Repair Implants/Regenerative Biologics $36.3MM, flat; Spine Regenerative Stimulati...
4Q12 and 2012 Revenue: Orthofix
$462.3MM, +0.4 4Q12 revenue: $112MM, -8% Spine Repair Implants/Regenerative Biologics $36.3MM, flat Spine Regenerative Stimulation $39.4MM, -7% Orthopaedics $36.4MM, -15% Highlights pertain to 4Q12.
BARE BONES® - January 7, 2013
Orthofix announced preliminary 4Q12 orthopaedic revenue of US $112MM and 2012 preliminary revenue of ~$462MM. (
BARE BONES® - October 24, 2012
Orthofix reported 3Q12 sales of US $114.8MM, +1% from 3Q11. (Spine $79.4MM, +4%: Stimulation $42.8MM, +8%, Implants/biologics $36.6MM, flat; Orthopaedics $35.4MM, -4%) (Growth...
3Q12 Earnings: Orthofix
$114.8MM, +1% Spine $79.4MM, +4% (Stimulation $42.8MM, +8%, Implants/biologics $36.6MM, flat) Orthopaedics $35.4MM, -4%   ~25% of sales across all business units is ex-U.S. Biologics alone grew 20% ...
2Q12: A First Look at Earnings
ORTHOWORLD’s estimates place preliminary 2Q12 market growth at 5% over 2Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 2Q12, unless otherwise noted. Exhibit 1 Orthopaedic Sales Increas...
BARE BONES® - July 26, 2012
Orthofix reported 2Q12 sales of US $119.5MM, +5% from 2Q11. (Spine $81.8MM, +7%: Stimulation $43.3MM, +9%, Implants/biologics $38.5MM, +4%; Orthopaedics $37.7MM, +2%) (Growth ...
First Look at Quarterly Results: 1Q12 vs. 1Q11
ORTHOWORLD’s preliminary estimates place overall 1Q12 market growth at 3% over 1Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 1Q12, unless noted otherwise. Exhibit 1 Orthopaedic Sales1 Increase...
BARE BONES® - April 26, 2012
Orthofix posted 1Q12 product sales of US $143.1MM, +5% from 1Q11. (Spine $75.0MM, +3%: Regenerative Stimulation $39.3MM, +2%, Repair/Biologics $35.8MM, +5%; Orthopaedics $41.0MM, +4%
Continuing 2011 Results, Including AAOS Conference Highlights
The orthopaedic industry appears to be tilting its focus from implant materials and toward implant alignment and personalization, per analyst review of the 2012 meeting of the American Academy of Orthopaedic Surgeons (AAOS). On the floor and in recent earnings calls, companies noted observatio...
3Q11: A First Look at Financials: Orthofix
ORTHOFIX $142.9MM, +3% * Spine $76.5MM, -1% (Stimulation $39.7MM, -8%, Implants/Biologics $36.8MM, +8%) * Orthopaedics $40.8MM, +8% * Sports Medicine $25.6MM, +7% * Mid-single-digit price erosion in spine * Sales of exfix an...
First Look at 2Q11 Results: Orthofix
ORTHOFIX $141.8MM, +2% * Spine $76.5MM, -3% (Stimulation $39.7MM, -12%, Implants/biologics $36.9MM, +9%) * Orthopaedics $40.1MM, flat * Sports Medicine $25.2MM, +8% * Ex-U.S. markets supporting growth in spine and ortho * Note...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group